

# Prof Mandeep Kaur

- Consultation times:
- Monday: 11:30- 12:00
- Wednesday: 12:00- 13:00

[Mandeep.kaur@wits.ac.za](mailto:Mandeep.kaur@wits.ac.za)

Office: GateHouse- 508

Practical reports to be submitted in the box at ground floor of MCB in GateHouse on the due date or handed-over to your TA before leaving the lab, as announced.

# Basic principles of drug discovery and development [electronic resource] / Benjamin E. Blass.

**Author** Blass, Benjamin, author.  
**Title** Basic principles of drug discovery and development [electronic resource] / Benjamin E. Blass.  
**Shelf #** RM 301.25 BLA  
**Imprint** London, UK : Elsevier/AP, [2015]  
©2015



E-Book

**Copies**

LOCATION

ONLINE (Bib)

Connect to  
[this title online. Multiple user license.](#)

SHELF NO

RM 301.25 BLA

STATUS

ONLINE

1 copy being processed for Biophy Library.

**Description** 1 online resource


**Note** Online resource; title from PDF title page (EBSCO, viewed April 29, 2015).

**Subject** Drug development.

Drugs -- Design.

**ISBN** 9780124115255

012411525X



# Basic Principles of Drug Discovery and Development

Author(s):

Benjamin Blass

ISBN: 978-0-12-411508-8

 [Add to Favorites](#)

Copyright © 2015 Elsevier Inc. All rights reserved.

## Table of Contents

  [Download PDFs](#) |  [Export](#) ▼

☐ [Front Matter, Copyright, Dedication, Foreword](#)

☐ [Chapter 1 - Drug Discovery and Development: An Overview of Modern Methods and Principles, Pages 1-34](#)

▶ [Abstract](#) |  [PDF \(929 K\)](#)

☐ [Chapter 2 - The Drug Discovery Process: From Ancient Times to the Present Day, Pages 35-86](#)

▶ [Abstract](#) |  [PDF \(3661 K\)](#)

☐ [Chapter 3 - Classical Targets in Drug Discovery, Pages 87-142](#)

▶ [Abstract](#) |  [PDF \(4457 K\)](#)

☐ [Chapter 4 - \*In vitro\* Screening Systems, Pages 143-202](#)

▶ [Abstract](#) |  [PDF \(2830 K\)](#)

☐ [Chapter 5 - Medicinal Chemistry, Pages 203-243](#)

▶ [Abstract](#) |  [PDF \(2182 K\)](#)

<b>Lecture and practical Schedule</b>	<b>Date</b>
<b>Lecture -1-2, Drug Discovery process, Methods and Principles</b>	<b>12<sup>th</sup> September</b>
<b>Lecture- 3-4, Methods and Principles, How do drugs work</b>	<b>13<sup>th</sup></b>
<b>Methods and Principles and Introduction to practical 1</b>	<b>14<sup>th</sup></b>
<b>Practical -1</b>	<b>17<sup>th</sup></b>
<b>Lecture 5-6, How do drugs work</b>	<b>19<sup>th</sup></b>
<b>Lecture 7-8, How do drugs work</b>	<b>20<sup>th</sup></b>
<b>Lecture 9</b>	<b>21<sup>st</sup></b>
<b>Public holiday</b>	<b>24<sup>th</sup></b>
<b>Lecture 10-11, Cell culturing, Screening Assays</b>	<b>26<sup>th</sup></b>
<b>Lecture 12-13, Medicinal Chemistry</b>	<b>27<sup>th</sup></b>
<b>Lecture 14, Intro to practical-2</b>	<b>28<sup>th</sup></b>
<b>Practical -2</b>	<b>01<sup>st</sup> October</b>
<b>Lecture 14-16, Animal Models</b>	<b>03<sup>rd</sup></b>
<b>Lecture 17-18, Apoptosis</b>	<b>04<sup>th</sup></b>
<b>Lecture 19, Intro to practical 3</b>	<b>05<sup>th</sup></b>
<b>Practical -3</b>	<b>08<sup>th</sup></b>
<b>Revision</b>	<b>10<sup>th</sup></b>
<b>Test</b>	<b>11<sup>th</sup></b>
<b>Lecture 22- Drug Approvals and IP</b>	<b>12<sup>th</sup></b>
<b>Lecture 23- Drug toxicity, Pharmacogenetics and use of translational biomarkers</b>	<b>15<sup>th</sup></b>
<b>ADME</b>	<b>17<sup>th</sup></b>
<b>ADME</b>	<b>18<sup>th</sup></b>
<b>ADME</b>	<b>19<sup>th</sup></b>
<b>Revision</b>	<b>22<sup>nd</sup></b>

# Drug Discovery Learning Outcomes

## **Background of drug discovery and development**

- Understand the broader concept of drug discovery and development.
- Explain different stages of drug development.
- Summarize methods and principles involved in the drug discovery process.
- Discuss the processes involved in target selection and hit identification.
- Compare properties of drug molecules to identify the clinical candidate.
- Explain different phases of clinical trials.
- Demonstrate knowledge of drug approval process.
- Use in silico example to demonstrate different phases of drug development.

# Drug Discovery Learning Outcomes

## Mechanisms of action of drugs

- Define the term 'druggable target'.
- Summarize known key drug targets (enzymes, GPCR, Ion channels, transporters) of drugs in the cell.
- Explain enzymatic mechanisms involved in drug action including substrate binding, enzyme catalysis etc.
- Show with diagrams how enzyme inhibitors work.
- Compare competitive and non-competitive inhibitors.
- Explain receptors and their functions.
- Explain structure of GPCRs and signalling pathways involved in their action.
- Summarize cAMP and IP<sub>3</sub> signaling pathways.
- Explain biology behind drug-receptor interactions
- Explain and compare agonists, antagonists with examples.
- Explain structure, function and gating mechanisms of Ion channels.
- List ways to modulate activity of ion channels.
- Define membrane transporter proteins.
- Differentiate between membrane transporter proteins and ion channels.
- Describe mechanisms involved in transporter inhibition by drugs.
- Explain therapeutic index.

# Drug Discovery Learning Outcomes

## Drug molecule screening methods including cell culturing

- Define bioassays and assay development.
- Differentiate between primary assays and secondary assays during drug screening process.
- Understand and differentiate between in vitro and in vivo screenings methods.
- Demonstrate understanding of biochemical and cell-based assays.
- Identify causes of assay variation.
- Explain high throughput screening methods.
- Underline importance of miniaturization and automation in drug screening.
- Comprehend mammalian cell culturing methods, instruments, and safety guidelines for performing cell-based assays in laboratory.
- Demonstrate knowledge of statistical parameters used during high throughput screening methods.
- Perform cell-based assays such as cell growth inhibition using trypan blue and cell death using apoptosis assay.
- Perform throughput assay in 96-well plate after treating cells with different concentrations of the test compounds.
- Perform statistical analysis to calculate percentage of viable cells after drug treatments, generate graphs based on data obtained.

# Drug Discovery Learning Outcomes

## **Fate of a drug and Pharmacokinetics**

- Outline the fate of drug in the body from intake till excretion.
- Differentiate between pharmacokinetics and pharmacodynamics.
- Explain ADME (Absorption, Distribution, metabolism and Excretion) processes.
- Explain with examples the physiological effects of ADME.
- List different enzyme involved in drug metabolism such as CYP450.
- Define terms related to drug such as clearance, volume of distribution, half-life and bioavailability.



# Drug Discovery Learning Outcomes

## **Concepts involved in drug toxicity, Pharmacogenetics and use of translational biomarkers**

- Define maximum tolerable dose of a compound.
- List types of toxicities (cardiac, liver, nervous system etc.) with examples.
- Explain why different individuals respond differently when given same drug.
- Define pharmacogenetics with example.
- Define the term 'Biomarker'.
- Demonstrate knowledge of use of biomarkers to advance drug development process.

## **Drug approval**

- Demonstrate understanding of the drug approval process
- Understand intellectual property issues around drug development.

# **From The Lab To Your Medicine Cabinet:**

---

## **A Pharmaceutical Drug's Journey**

Courtesy

Dr. Steven Hansel  
Sr. Director, Pfizer


Under license: <https://creativecommons.org/licenses/by-nc-nd/3.0/>

# Drug Repurposing




	Novel Drug	Drug Repositioning	Drug Repurposing
Cost	>\$1 Billion	\$300 Million	\$ 250K
Time to Get to Market	13-15 Years	6.5 years	3 Years
Success Rate	1 in 10,000	4 in 10	3 in 10

# The Drug Development Process



- The development process is difficult, time consuming, and expensive
- Project teams = key functional unit
  - Looking for individuals desiring team success





# The Food and Drug Administration



Regulates  
Pharmaceutical Market

Ensuring Human Safety &  
Efficacy

Federal Food, Drug, and  
Cosmetic Act



# Where do we start?

- Identify disease (metabolic diseases, inflammation, neuroscience) or indication (diabetes, rheumatoid arthritis, Alzheimer's) class
  - New Target Idea !

## Formation of discovery project team




- Biology experts share knowledge of target and develop tools to further study
- Chemistry engages to identify lead chemical matter to interact with desired target (receptor, enzyme, etc.)
- ADME experts understand what body does to the drug
- Toxicology experts evaluate the safety
- Pharmaceutical Sciences - Expertise in formulation & drug delivery





# Target Identification

- As disease biology is more fully understood, new potential drug intervention points are identified (receptors, enzymes, ion-channels, circulating agonists, etc.)”



# Target Validation

Clinical Proof of Concept (POC) =  
Right Target + Right Drug

- Evaluate target and confirm its role in the disease state
- Avoid research paths that lead to dead ends



DISCOVERY



# Creation of New Drug Molecule

---

- Where do chemical starting points (leads) come from?
  - High Throughput screening
  - Competitor information
  - Literature
  - Academia
  - Computer-Assisted Drug Design (CADD)



# Lead Optimization

---

- Chemically-related series that survive initial screening are then optimized to IMPROVE their safety and efficacy
- Structure-Activity Relationship (SAR) with chemical structure of a current drug




DISCOVERY




# Candidate Selection Stage of Drug Discovery

---



# Drug Substance Scale-Up



- Chemical engineers and industrial chemists make enough drug to use up through early clinical studies

**PRE-CLINICAL**

# The Preclinical Stage

---



**PRE-CLINICAL**



# Pre-Clinical Testing

---

- Evaluate 1–3 best compounds
- Higher TI ratio = safer medication



$$\text{Therapeutic Index (TI)} = \frac{\text{Drug concentration associated with safety finding}}{\text{Drug concentration associated with predicted human efficacy}}$$

# IND Application

- FDA must approve prior to First-in-Human (FIH) clinical trial
- Contains:
  - Acute toxicity of drug substance in at least 2 species of animal
  - Short-term toxicity studies
  - Pharmacological profile of drug substance





# IND Application

Sufficient data on  
safety & efficacy

Implication on human  
pharmacology

Protocols describing  
clinical studies in  
detail

The image shows a stack of FDA IND (Investigational New Drug) application forms. Overlaid on the forms are three orange rectangular boxes with white text, representing the review stages: Pharmacology/Toxicology Review, Chemistry Review, and Clinical Review. The forms themselves contain various fields for drug information, sponsor details, and study protocols.

Pharmacology/Toxicology  
Review

Chemistry Review

Clinical Review

Results from pre-  
clinical testing

Manufacture &  
analysis of chemical  
composition

Describe the  
qualification of  
personnel



# Phases of Clinical Trials

---

## 1 PHASE

- First-in-human (FIH) dosing to healthy volunteers
- Administration of single escalating doses of drug to a small number of subjects
- Short-term multiple doses (2 weeks)
- 10-15 volunteers
- Assess safety & PK

## 2 PHASE

- First dosing to patients
- Fewer dosages studied than in Phase I
- First evaluation of efficacy
- Safety profile & PK monitored.
- 20-100 subjects studied
- Assess Proof-of-Concept

## 3 PHASE

- Test effectiveness of drug for particular indication(s) in patients
- Common effects documented in larger population
- > 1,000 subjects
- Finalize prescribing label

## 4 PHASE

- Post-marketing approval studies
- Additional information about effectiveness and safety
- 300-3000 volunteers

# New Drug Application

Proposed labeling  
details for the  
product

Results on safety &  
efficacy of the drug

Results from clinical  
trials

The image shows a stack of New Drug Application (NDA) forms. The top form is clearly visible and is labeled 'APPLICATION TO MARKET FOR A NEW DRUG, BIOLOGIC, OR AN ANTIBIOTIC DRUG FOR HUMAN USE'. It is Form FDA 209 (10/95). The form is divided into several sections, including 'APPLICANT INFORMATION', 'APPLICATION DESCRIPTION', and 'MANUFACTURING INFORMATION'. It contains various fields for text entry and checkboxes for different types of applications (e.g., New Drug, New Combination, New Dosage Form, New Indication, New Route of Administration, New Manufacturer, New Labeling). The form is printed on white paper with black text and lines.

Details on long-term  
studies and post-  
marketing  
surveillance

Method of  
manufacture of drug  
and quality control  
analysis



# FDA Review of NDA

---

Pharmacology/Toxicology Review

Chemistry Review

Clinical Review

Statistician

Biopharmaceutical Review

Microbiological Review



- The FDA approval process may take 6-18 months.
  - FDA establishes the final label of new drug.
- Sponsor must file separately in every global region or country.

# Where do YOU fit in?

---

- Chemists
  - Medicinal, Synthetic, Analytical, Computational
- Biochemists
- Biologists
- Pharmacologists
- Pharmaceutical Scientists
  - Formulation, Physical Pharmacy, Pharmacokinetics
- M.D.s, Pharmacists, Nurses
- Mathematicians
- Automation experts
- Toxicologists
- Report Writers
- Human Resources
- Business
- Managers
- Animal Experts
- Regulatory Experts
- Marketing
- Sales